About this Journal Submit a Manuscript Table of Contents
ISRN Oncology
Volume 2013 (2013), Article ID 752792, 6 pages
Research Article

The Predictive Value of Cystatin C in Monitoring of B Non-Hodgkin Lymphomas: Relation to Biochemical and Clinical Parameters

1Department of Biochemistry, Faculty of Pharmacy, University of Tuzla, 75000 Tuzla, Bosnia and Herzegovina
2Clinic for Oncology, Haematology and Radiotherapy, University Clinical Centre Tuzla, 75000 Tuzla, Bosnia and Herzegovina
3Chair of Pharmaceutical Biology, Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia
4Department of Biotechnology, Jožef Stefan Institute, 1000 Ljubljana, Slovenia

Received 11 July 2013; Accepted 13 August 2013

Academic Editors: G. Gatti and G. E. Kim

Copyright © 2013 A. Softić et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Abrahamson, A. J. Barrett, G. Salvesen, and A. Grubb, “Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids,” Journal of Biological Chemistry, vol. 261, no. 24, pp. 11282–11289, 1986. View at Scopus
  2. Y. M. C. Henskens, E. C. L. Veerman, and A. V. N. Amerongen, “Cystatins in health disease,” Biological Chemistry Hoppe-Seyler, vol. 377, no. 2, pp. 71–86, 1996. View at Scopus
  3. P. Pierre and I. Mellman, “Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells,” Cell, vol. 93, no. 7, pp. 1135–1145, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. O. Simonsen, A. Grubb, and H. Thysell, “The blood serum concentration of cystatin C (γ-trace) as a measure of the glomerular filtration rate,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 45, no. 2, pp. 97–101, 1985. View at Scopus
  5. J. Kos, M. Krašovec, N. Cimerman, H. J. Nielsen, I. J. Christensen, and N. Brünner, “Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis,” Clinical Cancer Research, vol. 6, no. 2, pp. 505–511, 2000. View at Scopus
  6. I. Zore, M. Krašovec, N. Cimerman et al., “Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer,” Biological Chemistry, vol. 382, no. 5, pp. 805–810, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Kos, B. Štabuc, A. Schweiger et al., “Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients,” Clinical Cancer Research, vol. 3, no. 10, pp. 1815–1822, 1997. View at Scopus
  8. A. Mulaomerović, A. Halilbašić, E. Čičkušić, T. Zavašnik-Bergant, L. Begić, and J. Kos, “Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma,” Cancer Lett, vol. 248, pp. 192–197, 2007.
  9. H. A. Preti, F. Cabanillas, M. Talpaz, S. L. Tucker, J. F. Seymour, and R. Kurzrock, “Prognostic value of serum interleukin-6 in diffuse large-cell lymphona,” Annals of Internal Medicine, vol. 127, no. 3, pp. 186–194, 1997. View at Scopus
  10. N. Cimerman, P. M. Brguljan, M. Krašovec, S. Šuškovič, and J. Kos, “Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients,” Clinica Chimica Acta, vol. 300, no. 1-2, pp. 83–95, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Risch, R. Herklotz, A. Blumberg, and A. R. Huber, “Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients,” Clinical Chemistry, vol. 47, no. 11, pp. 2055–2059, 2001. View at Scopus
  12. T. Gruev, K. Chakalarovski, O. Stojceva-Taneva, A. Grueva, and K. Trenceva, “Effects of glucocorticoid immunosuppression on serum cystatin C levels,” Journal of Medical Biochemistry, vol. 28, no. 3, pp. 191–196, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Avilés, B. R. Narváez, J. C. Díaz-Maqueo, R. Guzmán, A. Talavera, and E. L. García, “Value of serum beta 2 microglobulin as an indicator of early relapse in diffuse large cell lymphoma,” Leukemia & Lymphoma, vol. 9, no. 4-5, pp. 377–380, 1993.
  14. J. Azocar, M. Essex, and A. Watson, “Changes in the expression of HLA and β2-microglobulin by cultured lymphoid cells,” Human Immunology, vol. 5, no. 4, pp. 283–293, 1982. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Hagberg, A. Killander, and B. Simonsson, “Serum β2-microglobulin in malignant lymphoma,” Cancer, vol. 51, no. 12, pp. 2220–2225, 1983. View at Scopus
  16. M. Legros, J. Ferriere, Y. Bignon, P. Chollet, G. Gaillard, and R. Plagne, “Serum β2 microglobulin: a good prognosis indicator in non-Hodgkin’s lymphoma,” Proceedings of the American Society of Clinical Oncology (ASCO), vol. 6, article 748, 1987.
  17. P. W. M. Johnson, J. Whelan, S. Longhurst et al., “β-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas,” British Journal of Cancer, vol. 67, no. 4, pp. 792–797, 1993. View at Scopus
  18. M. A. Shipp, “Prognostic factors in aggressive non-Hodgkin's lymphoma: who has “high- risk” disease?” Blood, vol. 83, no. 5, pp. 1165–1173, 1994. View at Scopus
  19. M.-M. Galteau, M. Guyon, R. Gueguen, and G. Siest, “Determination of serum cystatin C: biological variation and reference values,” Clinical Chemistry and Laboratory Medicine, vol. 39, no. 9, pp. 850–857, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Majello, R. Arcone, C. Toniatti, and G. Ciliberto, “Constitutive and IL-6-induced nuclear factors that interact with the human C-reactive protein promoter,” EMBO Journal, vol. 9, no. 2, pp. 457–465, 1990. View at Scopus
  21. E. Legouffe, C. Rodriguez, M. C. Picot et al., “C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma,” Leukemia and Lymphoma, vol. 31, no. 3-4, pp. 351–357, 1998. View at Scopus
  22. J. F. Seymour, M. Talpaz, F. Cabanillas, M. Wetzler, and R. Kurzrock, “Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma,” Journal of Clinical Oncology, vol. 13, no. 3, pp. 575–582, 1995. View at Scopus